Patents by Inventor Wenqiang PANG

Wenqiang PANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12226472
    Abstract: A type O foot-and-mouth disease virus-like particle antigen is provided, wherein the type O foot-and-mouth disease virus-like particle antigen is type O CATHAY topotype foot-and-mouth disease virus-like particle antigen, and the type O CATHAY topotype foot-and-mouth disease virus-like particle antigen is assembled by VP0, VP3 and VP1 antigen proteins of type O CATHAY topotype foot-and-mouth disease virus. The type O foot-and-mouth disease virus-like particle antigen has good immunogenicity. The prepared vaccine can produce complete protection against the O-type foot-and-mouth disease virus on the 14th day after immunization. The antibody titer produced is higher than that of the commercial inactivated vaccine, and the duration of immune protection can be maintained for at least 133 days. The prepared vaccine composition, preparation method and use thereof are also provided.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: February 18, 2025
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Yan Xiao, Wenqiang Pang, Jinzhong Sun, Xuke Zhang
  • Publication number: 20230149529
    Abstract: The present disclosure provides a type A foot-and-mouth disease virus-like particle antigen assembled by VP2, VP3 and VP1 antigen proteins of an epidemic strain of type A foot-and-mouth disease virus. The type A foot-and-mouth disease virus VP2 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 1 or its degenerate sequence, the type A foot-and-mouth disease virus VP3 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 2 or its degenerate sequence, and the type A foot-and-mouth disease virus VP1 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 3 or its degenerate sequence.
    Type: Application
    Filed: August 28, 2020
    Publication date: May 18, 2023
    Inventors: Kegong Tian, Wenqiang Pang, Yan Xiao, Xuke Zhang
  • Publication number: 20230048677
    Abstract: Provided is an African swine fever virus chimeric protein. The chimeric protein comprises: (1) an African swine fever virus p72 domain I; (2) an African swine fever virus p72 domain II; (3) an African swine fever virus p72 domain III; and (4) an African swine fever virus antigenic protein. By using African swine fever virus p72 protein as a skeleton, the chimeric protein provided in the present invention will exhibit antigenic epitopes of African swine fever virus antigenic proteins p54, p30, CD2v, and p12, achieve a good immune effect, and can produce significant humoral and cell-mediated immune response.
    Type: Application
    Filed: March 9, 2021
    Publication date: February 16, 2023
    Inventors: Kegong Tian, Wenqiang Pang, Xuke Zhang
  • Publication number: 20220096620
    Abstract: The present disclosure provides a type O foot-and-mouth disease virus-like particle antigen, wherein the type O foot-and-mouth disease virus-like particle antigen is type O CATHAY type foot-and-mouth disease virus-like particle antigen, and the type O CATHAY type foot-and-mouth disease virus-like particle antigen is assembled by VP0, VP3 and VP1 antigen proteins of type O CATHAY type foot-and-mouth disease virus. The type O foot-and-mouth disease virus-like particle antigen of the present disclosure has good immunogenicity. The prepared vaccine can produce complete protection against the O-type foot-and-mouth disease virus on the 14th day after immunization. The antibody titer produced is higher than that of the commercial inactivated vaccine, and the duration of immune protection can be maintained for at least 133 days. The disclosure also relates to the prepared vaccine composition, preparation method and use thereof.
    Type: Application
    Filed: January 15, 2019
    Publication date: March 31, 2022
    Inventors: Kegong Tian, Yan Xiao, Wenqiang Pang, Jinzhong Sun, Xuke Zhang
  • Patent number: 10821172
    Abstract: The present disclosure provides a vaccine composition comprising an immune amount of Fiber protein of egg drop syndrome virus or an immune amount of a live vector recombined with gene of the Fiber protein of egg drop syndrome virus and a veterinarily acceptable carrier.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: November 3, 2020
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Yi Cheng, Wenqiang Pang, Jinzhong Sun, Xuke Zhang
  • Publication number: 20180353595
    Abstract: The present disclosure provides a vaccine composition comprising an immune amount of Fiber protein of egg drop syndrome virus or an immune amount of a live vector recombined with gene of the Fiber protein of egg drop syndrome virus and a veterinarily acceptable carrier.
    Type: Application
    Filed: November 3, 2017
    Publication date: December 13, 2018
    Inventors: Kegong TIAN, Yi CHENG, Wenqiang PANG, Jinzhong SUN, Xuke ZHANG
  • Patent number: 10130702
    Abstract: The present disclosurerelates to a vaccine composition, wherein the vaccine composition comprises an immune amount of fowl adenovirus Fiber-2 protein or an immune amount of a live vector recombined with gene of the fowl adenovirus Fiber-2 protein, and a pharmaceutically acceptable carrier. The vaccine composition can provide effective immune protection against different serotypes of adenoviruses and provide a protection rate of 100% at low levels of immunogenic components, showing good immunological efficacy.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: November 20, 2018
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Wenqiang Pang, Jinzhong Sun, Xuke Zhang
  • Publication number: 20180161424
    Abstract: The present disclosure relates to a vaccine composition, wherein the vaccine composition comprises an immune amount of fowl adenovirus Fiber-2 protein or an immune amount of a live vector recombined with gene of the fowl adenovirus Fiber-2 protein, and a pharmaceutically acceptable carrier. The vaccine composition can provide effective immune protection against different serotypes of adenoviruses and provide a protection rate of 100% at low levels of immunogenic components, showing good immunological efficacy.
    Type: Application
    Filed: January 31, 2018
    Publication date: June 14, 2018
    Inventors: Kegong TIAN, Wenqiang PANG, Jinzhong SUN, Xuke ZHANG